STAT+: A standing ovation for RevMed, and caution for Akeso
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
